Edition:
United Kingdom

Profile: argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

127.52USD
22 May 2019
Change (% chg)

$-6.28 (-4.69%)
Prev Close
$133.80
Open
$134.53
Day's High
$135.00
Day's Low
$125.22
Volume
76,475
Avg. Vol
43,591
52-wk High
$135.50
52-wk Low
$63.81

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Company Address

argenx SE

Willemstraat 5
BREDA     4811 AH
P: +3176.3030488

Company Web Links